Syndax Pharmaceuticals, Inc. (SNDX)

20,80 +0,31 (+1,51%) Börsenschluss: 04:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 184

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael A. Metzger M.B.A.	CEO & Director	1,1M	126,68k	1971
Dr. Neil Gallagher M.D., Ph.D.	President, Head of Research & Development	720,46k	N/A	1964
Mr. Keith Alan Goldan CPA	CFO, Treasurer & Chief Accounting Officer	674,65k	N/A	1971
Mr. Luke J. Albrecht	Senior VP, General Counsel & Secretary	631,36k	387,36k	1979
Dr. Catherine Madigan M.D.	Chief Medical Officer	655,84k	N/A	1972
Dr. Peter Ordentlich B.Sc., Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	1969
Dr. Richard A. Heyman Ph.D.	Co-Founder	N/A	N/A	1957
Dr. Ronald M. Evans Ph.D.	Co-Founder, Advisor and Chair of Scientific Advisory Board	N/A	N/A	1949
Dr. Michael Downes Ph.D.	Co-Founder	N/A	N/A	N/A
Sharon Klahre	Vice President of Investor Relations & Communications	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.